CLINICAL DEVELOPMENT IN ONCOLOGY
Credit: Meletios Verras via
Shutterstock.com.
(tisagenlecleucel), Kite Pharma’s Yescarta (axicabtagene ciloleucel), and Kite Pharma’s Tecartus (brexucabtagene autoleucel), have been developed for various types of cancer. While these therapies have shown promise in clinical trials, they can also have significant side effects, requiring careful monitoring of patients.
Insurers and government programmes may be reluctant to cover costly treatments In August 2017, Kymriah broke ground by becoming the first CAR T-cell therapy in the world to gain approval to treat acute lymphoblastic leukaemia in the US, followed closely by Yescarta. Both therapies were approved in Europe the following year. The fact that these treatments were initially approved in the US shows how CAR-T development was centered primarily in the West, more specifically the US, in the mid-2010s. Between 2010 and 2014, more than half of newly identified CAR-T therapies were being developed or co-developed by a US-based company. Key major players in this field are
Novartis, Gilead, and Bristol Myers Squibb. Bristol Myers Squibb is one of the leading patent filers in the CAR T-cell therapy market. Obstacles within the CAR-T market are
mainly financial. CAR-T therapy is an expensive form of cancer treatment, with costs ranging from hundreds of thousands to millions of dollars per patient. This can create financial barriers for patients who are unable to afford the treatment, as well as for healthcare providers and insurers who may struggle to cover their costs. Due to the high cost of CAR-T therapy,
insurers and government programmes may be reluctant to cover the treatment. This can create challenges for patients and healthcare providers who are trying to access and administer the therapy. In addition to the cost of the therapy itself, there are also significant manufacturing costs associated with CAR-T therapy. These include the cost of developing and scaling up the manufacturing process, and of the specialised equipment and facilities needed to produce the therapy.
Clinical Trials in Oncology | 29
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44
